ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

Key Takeaways

• CROWN seven-year data: 55% Lorbrena progression-free survival likelihood versus 3% for crizotinib; median investigator-assessed PFS not reached; HR 0.19 (81% risk reduction).
• Pfizer planned more than 40 ASCO abstracts for May 29–June 2, 2026 in Chicago, including three late-breaking sessions.
• BREAKWATER Cohort 3 late-break covers first-line Braftovi plus cetuximab and FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer.
• TALAPRO-3 late-break tests Talzenna plus Xtandi earlier in HRR-altered metastatic castration-sensitive prostate cancer.

What did the Lorbrena CROWN seven-year update show?

In a Pfizer press release, the company reported unprecedented seven-year follow-up from Phase 3 CROWN comparing Lorbrena (lorlatinib) with Xalkori (crizotinib) in previously untreated ALK-positive advanced or metastatic NSCLC. At seven years, Lorbrena-treated patients had a 55% likelihood of remaining alive without disease progression (95% CI 46–63) versus 3% (95% CI 1–8) on crizotinib.

Investigator-assessed median PFS had not been reached with Lorbrena, with an estimated hazard ratio of 0.19 (95% CI 0.13–0.26). Pfizer said full results were presented in an ASCO 2026 oral session (Abstract #8502) and published simultaneously in Annals of Oncology. The randomized CROWN design enrolled 296 patients (NCT03052608).

Why do colorectal and prostate late-breakers still matter?

Pfizer’s ASCO 2026 oncology showcase release framed Lorbrena as established standard-of-care reinforcement while spotlighting earlier-line expansion plays. For colorectal cancer, a late-breaking BREAKWATER Cohort 3 presentation was scheduled to report PFS and OS for Braftovi (encorafenib) with cetuximab and FOLFIRI as first-line therapy in BRAF V600E-mutant metastatic disease, building on prior FDA full approval and ORR topline from that cohort.

In prostate cancer, TALAPRO-3 late-breaking data were positioned to show clinically meaningful radiographic PFS benefit for Talzenna plus Xtandi in metastatic castration-sensitive disease harboring homologous recombination repair alterations, with effects described as consistent across subgroups and a strong overall-survival trend — following March 2026 topline results.

How should competitors and investors read the meeting?

Durable first-line ALK control strengthens Lorbrena’s guideline and formulary narrative against sequential TKI strategies. BRAF colorectal and PARP-plus-AR pathway prostate readouts test whether Pfizer can move combinations earlier — where patient numbers and duration on therapy expand revenue more than late-line salvage niches.

• Lung: durability and CNS control narratives around third-generation ALK inhibition
• Colorectal: first-line BRAF regimen credibility versus chemotherapy backbones alone
• Prostate: earlier HRR-selected use of talazoparib plus enzalutamide

Registry detail for CROWN remains available on ClinicalTrials.gov NCT03052608, useful for confirming enrollment size (296) and endpoint structure when modeling peak share.

How should medical affairs translate the data?

Field teams should separate three conversations. First, ALK-positive NSCLC durability: seven-year landmark PFS supports first-line Lorbrena discussions with thoracic oncologists who still sequence older TKIs. Second, BRAF V600E metastatic colorectal cancer: BREAKWATER Cohort 3 is about whether a Braftovi triplet belongs in the initial regimen, not only after chemotherapy failure. Third, HRR-altered mCSPC: TALAPRO-3 asks whether PARP-plus-AR pathway blockade should move earlier than metastatic castration-resistant settings.

Competitive intelligence should also track abstract plain-language summaries Pfizer published for non-specialist audiences. Those summaries often preview the exact claims payers will see in AMCP dossiers within weeks of ASCO.

What remains unproven?

Seven-year landmark PFS probabilities are not the same as mature overall survival superiority in every subgroup. Late-breaking BREAKWATER and TALAPRO-3 effect sizes must be judged on the presented Kaplan–Meier curves and adverse-event tables, not on abstract titles alone. Pipeline MEK/BRAF combinations mentioned for melanoma remain early and should not be conflated with registrational CROWN evidence.

Related NovaPharma coverage

• EMA backs datopotamab deruxtecan for lung cancer access
• Merck–Harpoon therapeutics acquisition and oncology pipeline
• Cardiff Oncology pipeline update

Frequently Asked Questions

Primary Sources

1. Pfizer: Seven-year CROWN Lorbrena analysis
2. Pfizer: Oncology innovation showcase at ASCO 2026
3. ClinicalTrials.gov: CROWN NCT03052608